BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 23.10.2020 | 07:00

BB Biotech AG publishes its interim report

BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

23-Oct-2020 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media release as at October 23, 2020

Interim report of BB Biotech AG as at September 30, 2020

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2020, which covers the results of its business activities for the first nine months of 2020.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2020 amounted to CHF 26 mn (profit of CHF 172 mn in the same period 2019). In the third quarter a loss of CHF 395 mn (loss of CHF 382 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at September 30, 2020 can be downloaded at www.bbbiotech.com.

For further information:


Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch


www.bbbiotech.com

Company profile
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.


23-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Northern Data: "Waren zum richtigen Zeitpunkt mit dem richtigen Konzept am Markt"

Kryptowährungen, allen voran Bitcoin, sind zuletzt mit deutlichen Steigerungen wieder in den Investorenfokus gerückt. Northern Data, ein Spezialist für High Performance Computing, zählt laut eigenen Angaben zu den weltweit führenden Anbietern für Infrastruktur im Bereich Bitcoin-Mining. Wir haben mit dem Gründer und CEO Aroosh Thillainathan über die Perspektiven für Bitcoin und die Wachstumsaussichten für die Northern Data gesprochen.

News im Fokus

VOLKSWAGEN AG: Volkswagen AG veröffentlicht vorläufige Eckdaten für das Geschäftsjahr 2020

22. Januar 2021, 11:02

Aktuelle Research-Studie

HELMA Eigenheimbau AG

Original-Research: HELMA Eigenheimbau AG (von GBC AG): Kaufen

21. Januar 2021